Cerebras Systems' Stock Soars 68% on IPO Debut, Raising $5.55 Billion

نظرة سريعة

Cerebras Systems, an AI hardware firm, saw its stock surge 68% on its Nasdaq IPO debut, raising $5.55 billion, despite analyst skepticism over its niche technology's long-term viability.

ملخص مُنشأ بالذكاء الاصطناعي

حجم الخط

Cerebras Systems, an AI hardware firm, saw its stock surge 68% on its Nasdaq IPO debut, raising $5.55 billion, despite analyst skepticism over its niche technology's long-term viability.

Read the full article on CNBC

مواضيع ذات صلة

Cerebras Systems

مواضيعAI Hardware Nasdaq IPO Wafer Scale Engine 3 Nvidia

This article was originally published by CNBC.

أخبار ذات صلة

المزيد حول هذا الموضوعCerebras Systems

يتطور·49 dk önce

PepsiCo Reports Mixed Quarterly Results Amidst Consumer Budget Tightening

PepsiCo reported mixed second-quarter results, with strong international demand offsetting struggles in its North American food and beverage divisions. CEO Ramon Laguarta cited tightening consumer budgets due to inflation as a key factor impacting domestic performance.

CNBC

يتطور·1 sa önce

Gas Prices Could Rise Amid Renewed Tensions with Iran

Gas prices may increase as President Trump signals the end of a U.S.-Iran ceasefire, potentially pushing the national average towards $4 a gallon. Financial planners advise drivers to review budgets and cut discretionary spending.

CNBC

يتطور·2 sa önce

Luxshare Precision Industry's Hong Kong IPO Falls on Debut

Luxshare Precision Industry, a major Apple supplier, saw its shares end lower on their Hong Kong trading debut Thursday, despite raising $3.09 billion in its IPO, the largest this year. The stock closed down 1.55% after opening lower.

CNBC

يتطور·2 sa önce

South Korea's Kospi Enters Bear Territory Amid AI Skepticism and Market Concentration

South Korea's Kospi stock index has fallen into bear market territory, down over 20% from its record high, due to global investor skepticism about AI plays and extreme market concentration in chipmakers Samsung Electronics and SK Hynix.

CNBC

مُلِح·3 sa önce

AstraZeneca Shares Tumble After Heart Disease Drug Trial Fails

AstraZeneca's stock dropped nearly 9% after its experimental heart disease drug, Wainua, failed to meet its primary target in a late-stage clinical trial. The drug, intended for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), did not significantly reduce deaths or heart emergencies compared to a placebo.

CNBC

يتطور·5 sa önce

Luxshare Precision Industry Shares Dip on Hong Kong Debut After Record IPO

Luxshare Precision Industry's shares dropped over 5% in their Hong Kong trading debut Thursday, following its $3.09 billion IPO, the largest this year. The Apple supplier, already listed in Shenzhen, priced shares at HK$63.28, with the stock trading at HK$60 early on.

CNBC

المزيد حول هذا الموضوعCerebras Systems